Pilot Study Explores Safety of Intravenous BPC-157 in Healthy Humans

BPC-157 is a synthetic peptide known for its remarkable regenerative and anti-inflammatory properties, demonstrating efficacy in numerous preclinical models for conditions ranging from gastrointestinal ulcers to tendon and ligament injuries. While extensive animal data supports its therapeutic potential, the safety profile of intravenous BPC-157 administration in humans has remained largely unexplored, hindering its progression to clinical applications.

The study found that intravenous BPC-157 was generally well-tolerated across all tested doses, with no serious adverse events (SAEs) reported. A total of 3 mild, transient adverse events (e.g., mild headache, fatigue) were observed across the 24 participants, representing an overall incidence of 12.5%, which was comparable to the placebo group (1 event, 12.5% incidence). There were no statistically significant changes in vital signs, ECG parameters, or any clinical laboratory values (e.g., ALT, AST, creatinine) from baseline in any BPC-157 treatment group compared to placebo (p>0.05 for all primary safety endpoints). Specifically, liver enzyme levels remained within normal ranges, showing no 2-fold increase or greater in any participant. The highest dose of 10 µg/kg demonstrated a similar safety profile to the lower doses, suggesting a wide therapeutic window for intravenous administration.